DUBLIN – Versant Ventures is committing $35 million in series A funding to Bright Peak Therapeutics Inc., which is developing a pipeline of engineered cytokines that are produced using a novel chemical synthesis technique rather than the recombinant methods that have underpinned more than four decades of biotechnology development.
LONDON – Enthera Pharmaceuticals Srl has announced the largest international series A to date for an Italian biotech, closing a €28 million (US$32.9 million) round, to take programs in type 1 diabetes and inflammatory bowel disease (IBD) into phase I development.
LONDON - The combined force of Belgian life sciences has been brought together in the launch of Exevir Bio BV, which arrives on the scene with a €23 million (US$27 million) series A and ready for a phase I study of its novel antiviral therapy in hospitalized COVID-19 patients.
As Carmel, Ind.-based MBX Biosciences Inc., taking aim at rare endocrine diseases, disclosed $34.6 million in a series A financing, CEO and co-founder Kent Hawryluk told BioWorld that “everyone on the leadership team we’ve worked with in prior lives, so to speak,” adding that he’s “excited to have the band back together.”
Four IPOs from biopharmas chasing an aggregate $781.8 million launched on Friday with mixed results. Two of the companies, Inozyme Pharma Inc. and Annexon Inc., finished the day in positive territory while the other two, Iteos Therapeutics Inc. and Nurix Therapeutics Inc., saw their shares close flat.
HONG KONG – Looking to boost its R&D capacity, China’s Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd. launched an IPO on July 22 that raised ¥1.7 billion (US$240 million) on Shanghai’s STAR market. Shares (SSE:688336) almost doubled in value on the first day of trading, closing at ¥54.10, for a gain of 92%.
RSS
